AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,060,002 | -2.9% | 416,120 | +0.3% | 0.01% | 0.0% |
| Q2 2023 | $5,209,234 | +109822.6% | 414,748 | -2.9% | 0.01% | 0.0% |
| Q1 2023 | $4,739 | -1.3% | 427,336 | +8.6% | 0.01% | 0.0% |
| Q4 2022 | $4,803 | -99.9% | 393,395 | +5.6% | 0.01% | 0.0% |
| Q3 2022 | $3,888,000 | +6.9% | 372,425 | +9.9% | 0.01% | +20.0% |
| Q2 2022 | $3,638,000 | +34.3% | 338,780 | +18.5% | 0.01% | +66.7% |
| Q1 2022 | $2,708,000 | -25.0% | 285,906 | -8.5% | 0.00% | -25.0% |
| Q4 2021 | $3,611,000 | +19.6% | 312,598 | -1.2% | 0.00% | 0.0% |
| Q3 2021 | $3,020,000 | +1.3% | 316,281 | +2.3% | 0.00% | 0.0% |
| Q2 2021 | $2,981,000 | -1.6% | 309,263 | +0.8% | 0.00% | 0.0% |
| Q1 2021 | $3,031,000 | -61.2% | 306,827 | -9.4% | 0.00% | -63.6% |
| Q4 2020 | $7,818,000 | +65.4% | 338,607 | +1.1% | 0.01% | +57.1% |
| Q3 2020 | $4,728,000 | -23.7% | 334,834 | -18.5% | 0.01% | -30.0% |
| Q2 2020 | $6,196,000 | +80.2% | 410,896 | +10.4% | 0.01% | +42.9% |
| Q1 2020 | $3,439,000 | -1.1% | 372,187 | +4.2% | 0.01% | +16.7% |
| Q4 2019 | $3,478,000 | +27.7% | 357,037 | +5.1% | 0.01% | +20.0% |
| Q3 2019 | $2,724,000 | -31.8% | 339,666 | +6.2% | 0.01% | -28.6% |
| Q2 2019 | $3,992,000 | +14.9% | 319,875 | +25.3% | 0.01% | 0.0% |
| Q1 2019 | $3,473,000 | +43.6% | 255,343 | +1.2% | 0.01% | +40.0% |
| Q4 2018 | $2,418,000 | +17.3% | 252,354 | +48.0% | 0.01% | +25.0% |
| Q3 2018 | $2,062,000 | -28.2% | 170,562 | -7.2% | 0.00% | -33.3% |
| Q2 2018 | $2,871,000 | +10.0% | 183,812 | +5.9% | 0.01% | +20.0% |
| Q1 2018 | $2,610,000 | +14.6% | 173,506 | +9.7% | 0.01% | 0.0% |
| Q4 2017 | $2,277,000 | -3.8% | 158,231 | +0.9% | 0.01% | 0.0% |
| Q3 2017 | $2,366,000 | +69.7% | 156,881 | +13.3% | 0.01% | +66.7% |
| Q2 2017 | $1,394,000 | +44.0% | 138,438 | +2.0% | 0.00% | +50.0% |
| Q1 2017 | $968,000 | +48.9% | 135,748 | +3.8% | 0.00% | 0.0% |
| Q4 2016 | $650,000 | -26.3% | 130,790 | +9.8% | 0.00% | 0.0% |
| Q3 2016 | $882,000 | +50.5% | 119,144 | +11.1% | 0.00% | 0.0% |
| Q2 2016 | $586,000 | -27.1% | 107,288 | +12.8% | 0.00% | 0.0% |
| Q1 2016 | $804,000 | -11.7% | 95,118 | +1.2% | 0.00% | -33.3% |
| Q4 2015 | $911,000 | -36.9% | 93,948 | -8.9% | 0.00% | -40.0% |
| Q3 2015 | $1,443,000 | +25.2% | 103,128 | +26.5% | 0.01% | +25.0% |
| Q2 2015 | $1,153,000 | +1922.8% | 81,515 | +194.4% | 0.00% | – |
| Q1 2014 | $57,000 | -14.9% | 27,686 | -3.6% | 0.00% | – |
| Q4 2013 | $67,000 | 0.0% | 28,706 | 0.0% | 0.00% | – |
| Q3 2013 | $67,000 | -1.5% | 28,706 | -0.9% | 0.00% | – |
| Q2 2013 | $68,000 | – | 28,973 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |